Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:CRVS NASDAQ:EWTX NASDAQ:NAMS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$21.09-1.4%$21.76$19.69▼$28.35$3.66B0.831.21 million shs753,933 shsCRVSCorvus Pharmaceuticals$11.93+2.8%$14.00$3.55▼$26.95$975.45M0.841.75 million shs1.02 million shsEWTXEdgewise Therapeutics$34.83+2.7%$33.67$12.15▼$40.76$3.65B0.271.38 million shs927,412 shsNAMSNewAmsterdam Pharma$30.40+0.5%$33.49$17.63▼$42.21$3.54B0.071.29 million shs673,540 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+0.66%-1.50%-1.52%+3.78%-4.08%CRVSCorvus Pharmaceuticals+4.23%-0.75%-27.16%-24.07%+158.49%EWTXEdgewise Therapeutics+3.07%-8.86%-0.24%+14.67%+115.43%NAMSNewAmsterdam Pharma+3.17%-7.38%-22.19%+5.73%+47.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$21.09-1.4%$21.76$19.69▼$28.35$3.66B0.831.21 million shs753,933 shsCRVSCorvus Pharmaceuticals$11.93+2.8%$14.00$3.55▼$26.95$975.45M0.841.75 million shs1.02 million shsEWTXEdgewise Therapeutics$34.83+2.7%$33.67$12.15▼$40.76$3.65B0.271.38 million shs927,412 shsNAMSNewAmsterdam Pharma$30.40+0.5%$33.49$17.63▼$42.21$3.54B0.071.29 million shs673,540 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+0.66%-1.50%-1.52%+3.78%-4.08%CRVSCorvus Pharmaceuticals+4.23%-0.75%-27.16%-24.07%+158.49%EWTXEdgewise Therapeutics+3.07%-8.86%-0.24%+14.67%+115.43%NAMSNewAmsterdam Pharma+3.17%-7.38%-22.19%+5.73%+47.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.67Moderate Buy$31.6349.95% UpsideCRVSCorvus Pharmaceuticals 2.71Moderate Buy$33.33179.41% UpsideEWTXEdgewise Therapeutics 2.78Moderate Buy$44.2226.97% UpsideNAMSNewAmsterdam Pharma 2.83Moderate Buy$48.6059.87% UpsideCurrent Analyst Ratings BreakdownLatest CRVS, EWTX, ACAD, and NAMS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026EWTXEdgewise Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$50.00 ➝ $48.006/2/2026EWTXEdgewise Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$42.00 ➝ $45.006/1/2026EWTXEdgewise Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy$66.006/1/2026EWTXEdgewise Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$46.00 ➝ $52.005/8/2026ACADACADIA Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$33.00 ➝ $32.005/6/2026EWTXEdgewise Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$52.005/1/2026ACADACADIA Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)4/29/2026CRVSCorvus Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026NAMSNewAmsterdam Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026EWTXEdgewise Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026CRVSCorvus Pharmaceuticals The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$1.07B3.37$0.87 per share24.11$7.25 per share2.91CRVSCorvus PharmaceuticalsN/AN/A$0.13 per share91.51$0.73 per shareN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.93 per shareN/ANAMSNewAmsterdam Pharma$22.50M157.94N/AN/A$5.97 per share5.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$391M$2.209.5926.7026.8534.30%9.61%7.07%8/5/2026 (Estimated)CRVSCorvus Pharmaceuticals-$15.28M-$0.52N/AN/AN/AN/A-38.92%-35.75%8/6/2026 (Estimated)EWTXEdgewise Therapeutics-$167.79M-$1.66N/AN/AN/AN/A-32.55%-31.04%8/6/2026 (Estimated)NAMSNewAmsterdam Pharma-$203.82M-$1.79N/AN/AN/A-943.23%-26.49%-24.37%8/5/2026 (Estimated)Latest CRVS, EWTX, ACAD, and NAMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026CRVSCorvus Pharmaceuticals-$0.14-$0.15-$0.01-$0.15N/AN/A5/7/2026Q1 2026EWTXEdgewise Therapeutics-$0.50-$0.46+$0.04-$0.46N/AN/A5/7/2026Q1 2026NAMSNewAmsterdam Pharma-$0.46-$0.40+$0.06-$0.40$1.75 million$3.04 million5/6/2026Q1 2026ACADACADIA Pharmaceuticals$0.04$0.02-$0.02$0.02$280.25 million$268.10 million3/31/2026Q1 2026NAMSNewAmsterdam PharmaN/A-$0.40N/A-$0.40N/A$3.04 million3/12/2026Q4 2025CRVSCorvus Pharmaceuticals-$0.14-$0.15-$0.01-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/ACRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A3.593.48CRVSCorvus PharmaceuticalsN/A19.8119.81EWTXEdgewise TherapeuticsN/A22.6122.61NAMSNewAmsterdam PharmaN/A9.769.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%CRVSCorvus Pharmaceuticals46.64%EWTXEdgewise TherapeuticsN/ANAMSNewAmsterdam Pharma89.89%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.20%CRVSCorvus Pharmaceuticals19.70%EWTXEdgewise Therapeutics21.30%NAMSNewAmsterdam Pharma12.74%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510171.24 million126.37 millionOptionableCRVSCorvus Pharmaceuticals3084.09 million67.52 millionOptionableEWTXEdgewise Therapeutics60107.59 million84.68 millionOptionableNAMSNewAmsterdam Pharma4116.90 million102.01 millionOptionableCRVS, EWTX, ACAD, and NAMS HeadlinesRecent News About These CompaniesA Look At NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price WeaknessJune 11 at 8:53 AM | finance.yahoo.comNewAmsterdam Pharma Company N.V. (NAMS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 10 at 2:01 AM | seekingalpha.comCapital World Investors Raises Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMSJune 9 at 3:50 AM | marketbeat.comBillionaire Stanley Druckenmiller Likes This Small-Cap Pharma Stock in 2026June 8, 2026 | insidermonkey.comNewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Consensus Rating of "Moderate Buy" from AnalystsJune 4, 2026 | americanbankingnews.comNewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific SessionsJune 3, 2026 | globenewswire.comJTC Employer Solutions Trustee Ltd Purchases Shares of 75,500 NewAmsterdam Pharma Company N.V. $NAMSMay 29, 2026 | marketbeat.comNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in JuneMay 28, 2026 | globenewswire.comSwedbank AB Buys Shares of 90,900 NewAmsterdam Pharma Company N.V. $NAMSMay 28, 2026 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 65,000 SharesMay 28, 2026 | insidertrades.comLisanti Capital Growth LLC Buys 131,965 Shares of NewAmsterdam Pharma Company N.V. $NAMSMay 24, 2026 | marketbeat.comNewAmsterdam Pharma Company N.V. $NAMS Holdings Boosted by Legato Capital Management LLCMay 23, 2026 | marketbeat.comNewAmsterdam Pharma Company N.V.May 21, 2026 | edition.cnn.comNewAmsterdam Pharma Company N.V. (NAMS) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comNewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesMay 12, 2026 | finance.yahoo.comNewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL Trial - SlideshowMay 11, 2026 | seekingalpha.comNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in MayMay 11, 2026 | globenewswire.comNewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL Trial TranscriptMay 9, 2026 | seekingalpha.comDo NewAmsterdam Pharma’s (NAMS) Dilution Plans Reframe Its Path to Funding Ongoing Losses?May 8, 2026 | finance.yahoo.comNewAmsterdam Pharma Company NV (NAMS) reports Q1 loss, tops revenue estimatesMay 8, 2026 | msn.comNewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue EstimatesMay 7, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRVS, EWTX, ACAD, and NAMS Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$21.09 -0.30 (-1.40%) Closing price 04:00 PM EasternExtended Trading$21.30 +0.22 (+1.02%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Corvus Pharmaceuticals NASDAQ:CRVS$11.93 +0.33 (+2.84%) Closing price 04:00 PM EasternExtended Trading$12.36 +0.43 (+3.60%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Edgewise Therapeutics NASDAQ:EWTX$34.83 +0.90 (+2.65%) Closing price 04:00 PM EasternExtended Trading$35.01 +0.18 (+0.52%) As of 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.NewAmsterdam Pharma NASDAQ:NAMS$30.40 +0.14 (+0.46%) Closing price 04:00 PM EasternExtended Trading$31.49 +1.09 (+3.60%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
